Cancer clinical trials cooperative group
Appears in 1 story · Last updated Oct 27, 2026
Partner on EA2251 international trial
Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.
Updated Oct 27
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
